Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Chasing Compliance: The Global Regulatory Podcast

Generic Pharmaceuticals: Development, Testing, and Regulation

26 Mar 2021

Description

In this episode of Chasing Compliance, Jamie talks with Brandi Quinlin and Rebecca Lynch about generic drugs. The discussion ranges from what a generic drug is to how generic drugs are made, tested, and approved. Brandi and Rebecca also share their knowledge of drug formulation with some “delicious” analogies. Who knew chocolate chip cookies could reveal so much about generics? Lastly, they discuss regulatory requirement for getting a generic to market. Brandi Quinlin holds a master’s degree in regulatory affairs and brings years of experience in pharmaceutical development, generic development, pharmaceutical testing, and regulatory compliance. Rebecca Lynch is one of Global’s resident generic drug experts. She has a background in analytical method development and 25 years of experience in the generic pharmaceutical industry. 1:30 – What is a drug product? 4:30 – Active vs. inactive ingredients, what is the difference? 5:30 – What are key differences between immediate release and extended release and drug formulations? 12:00 – How do manufacturers select a compound/drug testing strategy? 17:40 – How do generic manufactures select a formulation and form factor? 23:30 – Are generics exact copies? 26:30 – Do generics need to go through clinical trials? 31:00 – What is the process for bringing a generic to market and what is required from a regulatory perspective? 37:30 – How does the FDA evaluate the formulations of generics? 45:40 – Favorite Friday Nights

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.